Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 10
    records per page




    Frequency and severity of Covid-19 in patients treated with biological Disease MESHD Modifying Anti-Rheumatic Drugs (bDMARDs) for inflammatory rheumatic disease MESHD. A case-control study

    Authors: Dr. Anne LOHSE; Dr. Marie BOSSERT; Dr. Ana-Maria BOZGAN; Charlotte BOURGOIN; Dr. Aline CHARPENTIER; Dr. Cerise GUILLOCHON; Dr. Julie KESSLER; Dr. Jean-Charles BALBLANC; Dr. Thierry CONROZIER

    doi:10.21203/rs.3.rs-50490/v1 Date: 2020-07-29 Source: ResearchSquare

    The aim of the study was to assess the impact (frequency and severity) of Covid-19 on patients treated with biological Disease MESHD Modifying Anti-Rheumatic Drugs (bDMARDs) for inflammatory rheumatic disease MESHD and to compare it to a control group consisting of patients with musculoskeletal conditions not treated with bDMARDs.Patients and methods:A case control study in 200 outpatients with musculoskeletal conditions. 100 consecutive patients who have been treated with bDMARDs and 100 other consecutive patients who did not take bDMARDs were asked to complete a 15-item standardized questionnaire regarding demographic data. The following information was recorded: gender TRANS, age TRANS, weight, height, body mass index, professional activity, family status, total number of children TRANS and number of children TRANS under 18, rheumatic disease MESHD diagnosis, current treatment for rheumatism, type of containment, close contact TRANS with Covid-19 patients, Covid-19 symptoms, Covid-19 test result and hospitalization for Covid-19.Results:bDMARD patients mostly suffered from rheumatoid arthritis MESHD rheumatoid arthritis HP, or RA, (47%) and ankylosing spondylitis MESHD (42%). The most prescribed bDMARDs were TNFα inhibitors (57%), IL-6 blockers (12%) and JAK inhibitors (11%). The mean duration of the current biological treatment was 38.6 months. Patients from the control group were suffering chiefly from osteoarthritis MESHD osteoarthritis HP (45%) and RA (21%). Compared to the control group, patients treated with bDMARDs were 10 years younger (p<0.001), fewer were retired (56% versus 31%) and more were on sick or incapacity leave (6% versus 18%). During lockdown, they were more likely to be working from home or working short term (27% versus 9%). 18 patients from the bDMARDs group stopped biological treatment: one because of Covid-19 evidenced by PCR, 11 because of symptoms suggesting Covid- 19 and only six from fear of contracting the disease MESHD. 12 patients, including the one Sars-CoV-2 +, resumed their treatment after a few weeks of interruption. There was no severe Covid-19 infection MESHD in the bDMARDs group. Among the three patients from the control group who had contracted Covid-19, one developed a very severe disease MESHD.Conclusion :This case-control study did not show an increase in the frequency or severity of Covid-19 in subjects suffering from chronic inflammatory rheumatism treated with biotherapies. Larger-scale studies are necessary before affirming that biologics do not expose patients to an increased risk of disease MESHD and complications.

    C-C chemokine receptor type 5 links COVID-19, Rheumatoid arthritis MESHD Rheumatoid arthritis HP, and Hydroxychloroquine

    Authors: Mahmood Yaseen Hachim; Ibrahim Hachim; Kashif Naeem; Haifa Hannawi; Issa Al Salmi; Suad Hannawi

    doi:10.21203/rs.3.rs-48001/v1 Date: 2020-07-23 Source: ResearchSquare

    Background: Patients with rheumatoid arthritis MESHD rheumatoid arthritis HP (RA) represent one of the fragile patient groups that might be susceptible to coronavirus disease MESHD -19 (COVID-19) and its severe form. On the other side, RA patients have been found not to have an increased risk of COVID19 infection MESHD. Moreover, some of the Disease MESHD-Modifying Anti-Rheumatic Drugs (DMARDS)  commonly used to treat rheumatic diseases MESHD like Hydroxychloroquine (HCQ) were proposed as a potential therapy for COVID19 with a lack of full understanding of their molecular mechanisms. This highlights the need for the discovery of common pathways that may link both diseases MESHD at the molecular side Methods: We used the in silico approach to investigate the transcriptomic profile of RA synovium compared to osteoarthritis MESHD osteoarthritis HP and healthy controls to identify RA specific molecular pathways shared with that of severe acute respiratory syndrome MESHD-corona virus-2 (SARS-COV-2) infected lung tissue. Results: Our results showed upregulation of chemotactic factors, including CCL4, CCL8, and CCL11, that all shared CCR5 as their receptor, as a common derangement observed in both diseases MESHD; RA and COVID-19. Moreover, our results also highlighted that HCQ might interfere with the COVID-19 infection MESHD through its ability to upregulate specific immune cell populations like activated natural killer (NK) cells, besides blocking CCR5 rich immune cell recruitment to the SARS-COV-2 infected lungs Conclusion: Our results might explain some of the reports that showed beneficial effects and indicate the need for proper patients stratification on their immune profile before selecting the therapeutic protocol or clinical trial enrollment. Keyword COVID-19, SARS-COV-2, Hydroxychloroquine, rheumatoid arthritis MESHD rheumatoid arthritis HP

    The impact of the COVID-19 Pandemic on Patients with Chronic Rheumatic Diseases MESHD: A Study in 15 Arab Countries

    Authors: Nelly Ziade; Lina el Kibbi; Ihsane Hmamouchi; Nizar Abdulateef; Hussein Halabi; Wafa Hamdi; Fatemah Abutiban; Manal el Rakawi; Mervat Eissa; Basel Masri

    doi:10.21203/rs.3.rs-40892/v1 Date: 2020-07-09 Source: ResearchSquare

    Aim. To evaluate the impact of the Coronavirus Disease MESHD 2019 pandemic (COVID-19) on the access to rheumatology care for patients with chronic rheumatic diseases MESHD (CRD) in the Arab countries.Method. A web-based cross-sectional survey was designed by the Arab Adult TRANS Arthritis MESHD Arthritis HP Awareness group (AAAA) consisting of 16 rheumatologists representing countries from the Arab League of Associations for Rheumatology (ArLAR), and was validated by the ArLAR scientific committee. The survey was disseminated through social media and patients' associations' channels between May 8 and May 22, 2020. The steering committee developed recommendations to improve the care of patients with CRD during the COVID-19 pandemic.Results. A total of 2163 patients were included in the analysis; 72% were females TRANS; mean age TRANS was 40 years (SD 11.9). The Levant, the Gulf, and North Africa contributed almost equally to the sample. The pandemic had a significant negative impact on rheumatology visits in 82% of cases, on access to hydroxychloroquine (47%), and on chronic medication persistency (28%). The negative impact on rheumatology visits was associated with female TRANS gender TRANS, country, medication non-persistency, isolation due to COVID-19, and impact on mental health. Sixty-one patients (2.8%) stated that they had COVID-19, 5% said that a close contact TRANS was infected, and 47% were in isolation because of COVID-19.Conclusion. The current study highlights the deleterious consequences of the COVID-19 pandemic on the continuity of rheumatology care. Therefore, an action plan, including establishing a telemedicine platform, securing drug availability, and promoting medication persistence through the appropriate communication channels, is strongly recommended.

    The impact of COVID-19 pandemic on rheumatology practice and rheumatologists: a cross-sectional multinational study

    Authors: Nelly Ziade; Ihsane Hmamouchi; Lina el Kibbi; Nizar Abdulateef; Hussein Halabi; Fatemah Abutiban; Wafa Hamdi; Manal el Rakawi; Mervat Eissa; Basel Masri

    doi:10.21203/rs.3.rs-40433/v1 Date: 2020-07-06 Source: ResearchSquare

    ObjectiveTo evaluate the impact of the COVID-19 pandemic on rheumatology practice and on the rheumatologists themselves, and to develop suggestions to improve the practice.MethodsA cross-sectional web survey was designed by members of the Arab League of Associations for Rheumatology (ArLAR), validated by its scientific committee and disseminated through e-mail and social media. It included close-ended questions about the impact of the pandemic on the activities (in percentage, where 100% corresponds to complete suspension), and open-ended questions about unmet needs. Univariate and multivariable logistic regression analyses were used to evaluate the predictors of impact. Suggestions were developed to improve practice.ResultsA total of 858 rheumatologists were included in the analysis (27.3% of registered), 37% were 35-44 years-old, 60% were females TRANS and 48% worked in the private sector. The impact of COVID-19 was a decrease of 69% in hospitalizations, 65% in outpatient clinic, 56% in infusion centers and 43% in income. It was associated with the region (highest in the Gulf), the use of telemedicine, the impact on income and the practice sector (lowest in private). Telemedicine was mostly based on traditional telephone contacts and e-mails and reimbursed in 12%. Fifteen rheumatologists (1.8%) were infected and 156 cases of COVID-19 among patients were reported, of whom 22% died. The top-cited unmet needs were: access to drugs and a telemedicine platform.Conclusion The negative COVID-19 pandemic on rheumatology practice may compromise rheumatic diseases MESHD control. Better access to drugs and providing telemedicine platforms are recommended to improve the practice. 

    C-C Chemokine Receptor Type 5 Links COVID-19, Rheumatoid Arthritis MESHD Rheumatoid Arthritis HP, and Hydroxychloroquine

    Authors: Mahmood Yaseen HACHIM; Ibrahim Y. Hachim; Kashif Naeem; Haifa Hannawi; Issa Al Salmi; Suad Hannawi

    doi:10.21203/rs.3.rs-37404/v1 Date: 2020-06-22 Source: ResearchSquare

    Background: Patients with rheumatoid arthritis MESHD rheumatoid arthritis HP (RA) represent one of the fragile patient groups that might be susceptible to coronavirus disease MESHD -19 (COVID-19) and its severe form. On the other side, RA patients have been found not to have an increased risk of COVID19 infection MESHD. Moreover, some of the Disease MESHD-Modifying Anti-Rheumatic Drugs (DMARDS)  commonly used to treat rheumatic diseases MESHD like Hydroxychloroquine (HCQ) were proposed as a potential therapy for COVID19 with a lack of full understanding of their molecular mechanisms. This highlights the need for the discovery of common pathways that may link both diseases MESHD at the molecular side Methods: We used the in silico approach to investigate the transcriptomic profile of RA synovium compared to osteoarthritis MESHD osteoarthritis HP and healthy controls to identify RA specific molecular pathways shared with that of severe acute respiratory syndrome MESHD-corona virus-2 (SARS-COV-2) infected lung tissue. Results: Our results showed upregulation of chemotactic factors, including CCL4, CCL8, and CCL11, that all shared CCR5 as their receptor, as a common derangement observed in both diseases MESHD; RA and COVID-19. Moreover, our results also highlighted that HCQ might interfere with the COVID-19 infection MESHD through its ability to upregulate specific immune cell populations like activated natural killer (NK) cells, besides blocking CCR5 rich immune cell recruitment to the SARS-COV-2 infected lungs Conclusion: Our results might explain some of the reports that showed beneficial effects and indicate the need for proper patients stratification on their immune profile before selecting the therapeutic protocol or clinical trial enrollment. Keyword COVID-19, SARS-COV-2, Hydroxychloroquine, rheumatoid arthritis MESHD rheumatoid arthritis HP

    Is health needs of chronic disease MESHD patients addressed during COVID-19 lockdown in India? A cross-sectional survey

    Authors: Aby Paul; Joel Joby; Sanjo Saijan; Jude James; Stelvin Sebastian; Basil John; Edwin Antony; Jobin Kunjumon

    doi:10.21203/rs.3.rs-36957/v1 Date: 2020-06-19 Source: ResearchSquare

    BackgroundThe novel corona virus disease MESHD (COVID-19) was declared as pandemic by World health organisation (WHO) on the 11th of March 2020. India was one among the countries in the world to declare the longest lock down across the nation in order to resist the spread of COVID-19. It was a challenge to assess the medical care of chronic disease MESHD patients during these lock down days.MethodologyWe adopted a cross sectional survey design to assess the health conditions and perceptions of patients with cardiovascular metabolic co-morbidities and those with autoimmune rheumatic diseases MESHD during the COVID-19 lock down daysResults and DiscussionA total of 310 patients completed the survey during this time period. Among these 310 responders, 299 completed the survey. We had 157(52.50%) patients with cardiovascular metabolic co-morbidities and 142(47.49%) with autoimmune rheumatic diseases MESHD. The mean age TRANS of patients in cardiovascular metabolic co-morbidities group was found to be 59.19±16.34 and those in autoimmune rheumatic diseases MESHD was 47.05±13.30. The predominant distribution of female TRANS gender TRANS for cardiovascular metabolic co-morbidities (57.32%) group and autoimmune rheumatic diseases MESHD (72.53%) is in accordance all the previous studies in this field.. The women are found to react more negatively in terms of to the same traumatic stress when compared with menConclusionIn conclusion there is strong need for health policy reformations in the field of the chronic diseases MESHD health care management to equip the preparedness in order respond adequately to such medical emergencies MESHD including natural disaster

    The impact of COVID-19 pandemic on pediatric rheumatology patients under immunosuppressive therapy: A single-center experience

    Authors: Oya Koker; Fatma Gul Demirkan; Gulsah Kayaalp; Figen Cakmak; Ayse Tanatar; Serife Gul Karadag; Emine Sonmez; Rukiye Omeroglu; Nuray Aktay Ayaz

    doi:10.21203/rs.3.rs-36583/v1 Date: 2020-06-19 Source: ResearchSquare

    Objective: The aim of the research was to further broaden current knowledge of whether severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) disease MESHD 2019 (COVID-19) entails a risk for children TRANS with rheumatic diseases MESHD regarding immunosuppressive treatment.Methods: Telephone-survey was administered by conducting interviews with the parents TRANS. A message containing a link to the actual questionnaire was sent to their phones simultaneously. The medical records of the patients were reviewed for gathering information about demographic data, clinical follow-up, and treatments.Results: Patients who were followed up with immunosuppressive treatment (n=439) were attempted to be contacted between 1 May 2020 and 15 May 2020. The diagnostic distribution of patients who were accessible and eligible for the study was as follows; juvenile idiopathic arthritis MESHD arthritis HP (JIA) (n=243, 58.7%), autoinflammatory diseases MESHD (n=109, 26.3%), autoimmune connective tissue diseases MESHD (n=51, 12.3%) and vasculitis MESHD vasculitis HP (n=11, 2.7%). In the entire cohort, the mean age TRANS was 12 ± 4.7 years, and 54.1% (n=224) of the patients were female TRANS. One patient with seronegative polyarticular JIA, previously prescribed methotrexate and receiving leflunomide during pandemic has been identified to be diagnosed with COVID-19. None of the patients, including the patient diagnosed with COVID-19, had any severe symptoms. More than half of the patients with household contacts TRANS required hospitalization as they were asymptomatic TRANS.Conclusion: Although circumstances such as compliance in social distancing policy, transmission TRANS patterns, attitude following contact may influence the results, immunosuppressive treatment does not seem to pose additional risk in terms of COVID-19.

    The Psychological State and Changes in the Routine of the Patients with Rheumatic Diseases MESHD during the First Month of the Lockdown of the Coronavirus Disease MESHD (COVID-19) Outbreak in Turkey

    Authors: Emire Seyahi; Burc Cagri Poyraz; Necdet Sut; Selma Akdogan; Vedat Hamuryudan

    doi:10.21203/rs.3.rs-33318/v1 Date: 2020-06-04 Source: ResearchSquare

    Objective: We hypothesized that patients with rheumatic diseases MESHD (RD) would have increased psychological distress during the COVID-19 outbreak; therefore assessed their psychological symptoms and changes in their routine.  Methods: A web-based study was conducted in a cross-sectional design in 3 groups of participants: 1. patients with RD, 2. hospital workers and 3. high-school teachers/non-medical academic staff. Psychiatric status was evaluated using Hospital Anxiety HP and Depression Scale and Impact of Event Scale-Revised scale.Results: We studied 771 patients with RD, 535 hospital workers, and 917 teachers/academic staff. Most of the patients with RD were unwilling to go to the hospital (86 %) while 22 % discontinued their medications (78%). Biological DMARDS were the most frequent drugs whose doses were altered. Only 4 % were willing to take hydroxychloroquine for protection. Moreover, the frequency of anxiety HP (20%), depression (43%) and post-traumatic stress (28%) among patients with RD were found to be comparable to that among the teachers/academic staff (23%, 43% and 29%, respectively), whereas significantly less than that among the hospital workers (40%, 62% and 46%, respectively) (p<0.0001). Female gender TRANS, over social media exposure, comorbid disease MESHD, or a psychiatric disorder were found to be independently associated with psychiatric symptoms in total study population. Conclusions: The majority of the patients were unwilling to attend outpatient visits and one fifth skipped or stopped their immunosuppressive agents. Psychiatric symptoms in patient’s and teacher’s populations were of considerable clinical concern, despite being significantly lower than that observed among the hospital workers.

    Hydroxychloroquine; Why It Might Be Successful and Why It Might Not Be Successful in the Treatment of Covid-19 Pneumonia MESHD Pneumonia HP? Could It Be A Prophylactic Drug?

    Authors: Omer Deniz

    id:10.20944/preprints202004.0348.v3 Date: 2020-05-12 Source: Preprints.org

    According to current literature and preliminary data, hydroxychloroquine (HCQ) seems potentially effective in the treatment of patients with Covid-19 pneumonia MESHD pneumonia HP. The concentrations of HCQ in lungs might be well above that of plasma SERO. Most likely, this property of HCQ provides effective drug concentrations in lungs. HCQ has a gradual onset of action in the treatment of rheumatic diseases MESHD. This could be valid for the treatment of Covid-19 pneumonia MESHD pneumonia HP. It was suggested that regular HCQ administration in animals for a certain time might result in gradual accumulation of HCQ in tissues. Reduced perfusion, somewhat distorted architecture of lung tissue, edema MESHD edema HP and, suggested gradual accumulation of HCQ in lung tissue might cause reduced HCQ concentrations in pneumonic areas of the lungs in Covid-19 pneumonia MESHD pneumonia HP. Patients with Covid-19 pneumonia MESHD pneumonia HP and extensive lung involvement might have less HCQ concentrations in their lungs than patients having limited lung involvement. Furthermore, patients with Covid-19 pneumonia MESHD pneumonia HP and extensive lung involvement might have more viral load than patients having limited lung involvement. That’s why treatment of patients with advanced Covid-19 pneumonia MESHD pneumonia HP using HCQ might result in treatment failure, however HCQ might be effective in the treatment of patients with mild and moderate Covid-19 pneumonia MESHD pneumonia HP. Using HCQ in Covid-19 pneumonia MESHD pneumonia HP prophylaxis seems logical since providing enough accumulation of HCQ in the healthy lungs, before the arrival of the SARS-CoV-2 virus, might prevent Covid-19 pneumonia MESHD pneumonia HP. However, the purpose of this paper is not to recommend using or not using HCQ for the treatment or for the prophylaxis of Covid-19 pneumonia MESHD pneumonia HP. The purpose of this paper is only to try to bring a new perspective on the role of HCQ in the treatment or in the prophylaxis of Covid-19 pneumonia MESHD pneumonia HP. This paper proposes only hypotheses, which need further researches to be confirmed.

    Knowledge, Attitude and Practice towards COVID-19 among Patients with Musculoskeletal and Rheumatic Diseases MESHD in Nepal: A Web- based Cross-Sectional Study

    Authors: Dr. Binit Vaidya; Dr. Manisha Bhochhibhoya; Dr. Rikesh Baral; Dr. Shweta Nakarmi

    doi:10.21203/rs.3.rs-24451/v1 Date: 2020-04-22 Source: ResearchSquare

    Introduction/objectives: The global health crisis created by Coronavirus Disease MESHD (COVID-19) can be a serious concern to rheumatologists. The relationship of rheumatic diseases MESHD, their therapies, and COVID-19 with multiple genuine and malicious information available online can influence the knowledge and attitude of rheumatic patients. This web-based google-form study was conducted to understand the knowledge, attitude and practices of rheumatologic patients towards COVID-19 in Nepal. Methodology: A web based cross-sectional study was conducted among the patients with rheumatic diseases MESHD. Modified version of questionnaire prepared by Zhong BL et al was used after consent. It was then translated in Nepali language for comprehensibility. The final questionnaire contained a total of 29 questions; 6 for demographic parameters, 12, 5 and 6 for knowledge, attitude and practice behaviors, respectively. Simple descriptive statistics describing the positive responses in each domain. Multiple linear regression analysis done to observe demographic variables associated with the knowledge, attitude and practice. Results: Among 380 participants, 63.2% were female TRANS. Most of the participants were aware of the clinical features of COVID-19 (91.6 %), 71.5% had positive attitude towards its control, some (31.5 %) thought that they had greater chance of getting COVID-19 than others and 18.9 % believed that the anti-rheumatic medications could increase their susceptibility to infection MESHD. Majority (> 94.7%) practiced preventive measures.Conclusions: Patients with rheumatic diseases MESHD were aware of the general clinical features, route of transmission TRANS and general preventive measures regarding COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.